Baidu
map

Br J Surg:甲状腺乳头状癌术中未预防性清扫颈淋巴结的结局分析

2016-02-17 Mechront 译 MedSci原创

甲状腺乳头状癌(PTC)的治疗过程中是否需要预防性清扫颈淋巴结(CND)仍存在争议。研究者纳入了1986-2010年间没有行CND的所有PTC患者。在术前和围手术期,对所有患者的颈部进行仔细的临床评估,是否存在任何可疑需切除的淋巴结组织。该队列中包含了淋巴结切除的患者,但是没有一例患者是经过了正式的颈部解剖的淋巴结清扫。通过Kaplan-Meier方法计算患者的无复发生存率(RFS)和颈部中央RF

甲状腺乳头状癌(PTC)的治疗过程中是否需要预防性清扫颈淋巴结(CND)仍存在争议。

研究者纳入了1986-2010年间没有行CND的所有PTC患者。在术前和围手术期,对所有患者的颈部进行仔细的临床评估,判断是否存在任何可疑需切除的淋巴结组织。该队列中包含了淋巴结切除的患者,但是没有一例患者经过了正式的颈部解剖的淋巴结清扫。通过Kaplan-Meier方法计算患者的无复发生存率(RFS)和颈部中央RFS以及基本特异性生存率(DSS)。

该研究涉及的1798名患者中有397人(22.1%)为男性,有1088人(60.5%)年龄≥45岁,有539人(30.0%)伴有pT3或pT4疾病。有742人(41.3%)接受了放射性碘的辅助治疗。中位数随访46个月,5年DSS为100%,5年RFS为96.6%,5年颈部中央RFS为99.1%。

研究结果表明,在术前和术中对PTC患者颈部中央进行详细的观察,以确认是否有颈部中央淋巴结转移是安全的。

原始出处:

Nixon IJ, Wang LY,et al.Outcomes for patients with papillary thyroid cancer who do not undergo prophylactic central neck dissection.Br J Surg. 2016 Feb;103(3):218-25. doi: 10.1002/bjs.10036.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044966, encodeId=38ce2044966bd, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Tue Jul 26 01:35:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034749, encodeId=02f22034e4917, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 27 14:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72501, encodeId=56b2e25018a, content=这个研究要好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:11:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292967, encodeId=e2ce129296e25, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Feb 19 11:35:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363786, encodeId=e4c91363e86bd, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Fri Feb 19 11:35:00 CST 2016, time=2016-02-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044966, encodeId=38ce2044966bd, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Tue Jul 26 01:35:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034749, encodeId=02f22034e4917, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 27 14:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72501, encodeId=56b2e25018a, content=这个研究要好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:11:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292967, encodeId=e2ce129296e25, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Feb 19 11:35:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363786, encodeId=e4c91363e86bd, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Fri Feb 19 11:35:00 CST 2016, time=2016-02-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044966, encodeId=38ce2044966bd, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Tue Jul 26 01:35:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034749, encodeId=02f22034e4917, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 27 14:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72501, encodeId=56b2e25018a, content=这个研究要好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:11:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292967, encodeId=e2ce129296e25, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Feb 19 11:35:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363786, encodeId=e4c91363e86bd, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Fri Feb 19 11:35:00 CST 2016, time=2016-02-19, status=1, ipAttribution=)]
    2016-03-22 Gsurgeon

    这个研究要好好看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2044966, encodeId=38ce2044966bd, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Tue Jul 26 01:35:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034749, encodeId=02f22034e4917, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 27 14:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72501, encodeId=56b2e25018a, content=这个研究要好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:11:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292967, encodeId=e2ce129296e25, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Feb 19 11:35:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363786, encodeId=e4c91363e86bd, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Fri Feb 19 11:35:00 CST 2016, time=2016-02-19, status=1, ipAttribution=)]
    2016-02-19 sodoo
  5. [GetPortalCommentsPageByObjectIdResponse(id=2044966, encodeId=38ce2044966bd, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Tue Jul 26 01:35:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034749, encodeId=02f22034e4917, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Aug 27 14:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72501, encodeId=56b2e25018a, content=这个研究要好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:11:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292967, encodeId=e2ce129296e25, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Feb 19 11:35:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363786, encodeId=e4c91363e86bd, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Fri Feb 19 11:35:00 CST 2016, time=2016-02-19, status=1, ipAttribution=)]

相关资讯

JCEM:雌激素诱导甲状腺乳头状癌细胞的自噬

甲状腺乳头状癌(PTC)的发生率在性别中的比例是女:男(1:3),关于性别差异的风险因素知之甚少。越来越多的研究认为雌激素在甲状腺肿瘤的发生中起重要作用,但是相关的机制并不清楚。近来有研究发现雌激素受体α(ER-α)可通过刺激活性氧的生成和胞外信号调节激酶诱导PTC的自噬。 研究者分析了ER-α在PTC患者甲状腺组织中的表达。通过化学和基因技术抑制PTC细胞自噬,检测PTC细胞的活力、增殖和

Clin Endocrinol:BRAF基因多态性与中国人甲状腺乳头状癌有关

背景:甲状腺乳头状癌(PTC),占甲状腺癌的80%以上,并且这个数据还在逐年增长。近年,研究认为BRAF基因的单核苷酸多态性(SNPs)是PTC的广泛认可的风险因素。本研究目的是,检测中国人中BRAF常见的基因突变是否与PTC的发生风险显著相关。 方法:我们通过 · 2015-05-10

-->

女性同时患皮脂腺癌、甲状腺乳头状癌和乳腺癌:病例报告

引言          单一个体或多个家族成员出现多种不同的肿瘤应怀疑内患者遗传易感性病变[1,2]。肿瘤抑制基因(如Cowden综合征的PTEN基因和乳腺癌的 BRCA1/2基因)通过引发细胞凋亡和G1周期停滞发挥作用。然而,表达和组织特异性剪接可能导致剪接变异体(SVs)和随后下游信号结果的差异性表达。由于癌症相关基因的剪接修饰改变

Baidu
map
Baidu
map
Baidu
map